Coronavirus Update: Moderna Hold Up, Sanofi and Regeneron's Kevzara Fails In Phase III
IL-6 Drugs Down But Not Out
Delay to Moderna's Phase III plans adds to the biotech's rollercoaster ride, but its CEO insists it is still on track.
You may also be interested in...
A study presented at a recent MIT-sponsored conference used network medicine to uncover dozens of potential opportunities for existing drugs to be repurposed for COVID-19.
Sanofi/Regeneron are ending development of Kevzara for COVID-19 after Phase III disappointments. Meanwhile Regeneron is ramping up biologics manufacturing in Ireland as it makes way for COVID-19 antibody production in New York, and multiple vaccines move forward in Japan with new funding and trials.
Disappointment as Roche/Chugai antibody tocilizumab misses most endpoints.